Table 3. Multivariable analyses of factors associated with survival outcomes.
| OS | DFS | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| ER (–) vs. ER (+) | * | 0.302 | 1.871 (1.061–3.300) | 0.030 |
| PR (–) vs. PR (+) | * | 0.215 | 1.826 (1.032–3.232) | 0.039 |
| Ki67 | ||||
| >14% vs. ≤14% | * | 0.662 | * | 0.189 |
| Molecular subtype | 0.000 | * | 0.227 | |
| Luminal B vs. Luminal A | 6.160 (1.879–20.190) | 0.003 | * | 0.056 |
| HER2-overexpressing vs. Luminal A | 11.562 (3.119–42.857) | 0.000 | * | 0.931 |
| TNBC vs. Luminal A | 12.091 (3.623–40.351) | 0.000 | * | 0.561 |
| The number of axillary involved lymph nodes | 0.013 | 0.000 | ||
| N1 vs. no | 1.177 (0.528–2.624) | 0.691 | 0.941 (0.508–1.741) | 0.846 |
| N2 vs. no | 1.855 (0.879–3.914) | 0.105 | 2.207 (1.298–3.753) | 0.003 |
| N3 vs. no | 3.202 (1.489–6.888) | 0.003 | 3.331 (1.905–5.824) | 0.000 |
| Involvement of infraclavicular lymph node | ||||
| No vs. yes | 0.544 (0.305–0.973) | 0.040 | 0.568 (0.354–0.913) | 0.019 |
| SCLD | ||||
| No vs. yes | * | 0.403 | * | 0.405 |
*, HR (95% CI) was not given when P>0.05 in Cox proportional hazards regression analysis. ER, estrogen receptor; PR, progestational hormone; HER-2, human epidermal growth factor receptor-2; TNBC, triple negative breast cancer; SCLD, supraclavicular lymph node dissection.